Treatment of Angioedema

Introduction to Angioedema Treatment

The American Academy of Allergy, Asthma, and Immunology recommends first-line treatment for angioedema with specific targeted therapies including plasma-derived C1 inhibitor, icatibant, or ecallantide, as these have been shown to be safe and efficacious for acute angioedema attacks 1, 2

Angioedema can be classified as either hereditary angioedema (HAE), acquired C1 inhibitor deficiency, ACE inhibitor-induced, or allergic/histamine-mediated, and the American Academy of Allergy, Asthma, and Immunology suggests assessing for airway compromise immediately 1, 2
The American College of Allergy, Asthma, and Immunology recommends evaluating for potential triggers such as medications, especially ACE inhibitors, trauma, emotional stress, or hormonal factors 3

For hereditary angioedema (HAE) attacks, the European Academy of Allergy and Clinical Immunology suggests first-line treatments including plasma-derived C1 inhibitor (1000-2000 U intravenously) and icatibant (30 mg subcutaneously) 4, 3
For ACE inhibitor-induced angioedema, the American Heart Association recommends immediate management including discontinuing the ACE inhibitor permanently and considering bradykinin pathway-targeted therapies such as icatibant (30 mg subcutaneously) 5

The American Academy of Allergy, Asthma, and Immunology recommends symptomatic management for all types of angioedema, including analgesics, antiemetics, and aggressive hydration for abdominal attacks, and monitoring for signs of impending airway closure for laryngeal attacks 1, 2
The American College of Allergy, Asthma, and Immunology suggests that self-administration of medication should be encouraged when appropriate, as it significantly reduces time to treatment and improves outcomes 6

The American Academy of Allergy, Asthma, and Immunology notes that standard angioedema treatment modalities (epinephrine, corticosteroids, antihistamines) are NOT effective for HAE or ACE inhibitor-induced angioedema 7, 1
The European Academy of Allergy and Clinical Immunology recommends that early treatment is critical, and on-demand treatment is most effective when administered as early as possible in an attack 6

The American Academy of Allergy, Asthma, and Immunology recommends short-term prophylaxis before dental or surgical procedures, including plasma-derived C1 inhibitor (1000-2000 U intravenously) and androgens (danazol 2.5-10 mg/kg) 1, 3
The American College of Allergy, Asthma, and Immunology suggests long-term prophylaxis for frequent attacks, including androgens (danazol 100 mg on alternate days) and antifibrinolytic agents (tranexamic acid 30-50 mg/kg/day) 3

The American Academy of Allergy, Asthma & Immunology recommends immediate and permanent discontinuation of the ACE inhibitor, with close observation in a controlled environment for potential intubation, as the cornerstone of treatment for ACE inhibitor-induced angioedema 8, 9

The American Academy of Allergy, Asthma & Immunology guidelines state that efficacy of icatibant and fresh frozen plasma have been described for ACE-I–associated angioedema; however, no controlled studies have been reported, representing a Grade A recommendation acknowledging FFP's described efficacy, though without controlled trial support 8, 9

FFP should only be used when bradykinin-targeted therapies (icatibant, C1 inhibitor) are not readily available, and symptoms are severe, according to the American Academy of Allergy, Asthma & Immunology 8, 9
The American Academy of Allergy, Asthma & Immunology recommends observing all patients in a facility capable of emergency intubation or tracheostomy, and considering elective intubation early if signs of impending airway closure develop 8, 9

The American Academy of Allergy, Asthma & Immunology recommends never restarting the ACE inhibitor, as patients experiencing angioedema with one ACE inhibitor will typically react to others (class effect) 8
The American Academy of Allergy, Asthma & Immunology notes that switching to an ARB carries a modest recurrence risk (2-17%), though most patients tolerate ARBs without recurrence 8, 9

Lisinopril, as an ACE inhibitor, blocks the breakdown of bradykinin, a vasoactive peptide that increases vascular permeability and causes tissue swelling, which can lead to angioedema and peripheral edema, according to the American Heart Association 10, 11
Angioedema occurs in less than 1% of patients taking ACE inhibitors, but occurs more frequently in Black patients and women, as reported by the American College of Cardiology 12

The American College of Cardiology recommends assessing volume status and considering diuretic adjustment if on concurrent diuretics for patients with simple peripheral edema 13, 14
For patients with angioedema, the American Heart Association recommends permanently discontinuing lisinopril and considering bradykinin-targeted therapies, such as icatibant or C1 esterase inhibitor 10, 11

Lack of response to epinephrine, antihistamines, and corticosteroids strongly suggests bradykinin‑mediated angioedema rather than histamine‑mediated allergic angioedema. 15
Bradykinin‑mediated angioedema does not improve with standard allergic therapies (epinephrine, antihistamines, steroids). 15
Urticaria is typically absent in bradykinin‑mediated angioedema, helping differentiate it from allergic angioedema. 15

ACE‑inhibitor‑induced angioedema is caused by impaired degradation of bradykinin, leading to excess bradykinin‑driven vascular permeability. 15
The swelling in angioedema occurs in submucosal tissues rather than airway smooth‑muscle constriction; therefore it is not a bronchospastic process. 16

In patients with ACE‑inhibitor‑induced angioedema, the offending ACE inhibitor should be permanently discontinued; residual swelling may persist for up to six weeks after cessation. 15

Continuing epinephrine, antihistamines, or corticosteroids after bradykinin‑mediated angioedema is suspected provides no benefit and delays appropriate therapy. 15
Using nebulized bronchodilators (e.g., albuterol) is ineffective because they target bronchospasm, not the submucosal edema of angioedema. 16
Nebulized medications, including nebulized tranexamic acid, are unsuitable for angioedema because the condition does not involve airway smooth‑muscle constriction. 16

Misidentifying bradykinin‑mediated angioedema as allergic angioedema leads to the use of ineffective treatments and worsens outcomes. 15